San Francisco-based iRhythm designed the next-generation Zio long-term ambulatory cardiac monitor to detect potential cardiac arrhythmias. Zeus, the company’s advanced, deep-learned AI algorithm, supports the capture and analysis of ECG data recorded by Zio. The company secured CE mark based on compliance to EU medical device regulation (MDR) standards.

Zio builds on the previous-generation Zio XT with long-term, continuous cardiac monitoring. It provides an end-to-end experience for patients with potential arrhythmias and demonstrates 99% patient compliance. iRhythm launched the next-generation monitor in the U.S. in September and expects widespread availability this year.